Company profile
Ovid Therapeutics Inc.
NASDAQ: OVID · Healthcare · Biotechnology
#669 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
49DFH 57DQ 40GM 39SS 54
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ growth stability, 3-yr revenue growth
Methodology →Revenue TTM
$7.1M
Rev growth YoY (TTM)
+1199.6%
Net income (FY)
-$17.4M
Employees
23
as of 2026-08-12
Market cap
$481.5M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.3M$7.3M2025
Net income-$17.4M-$17.4M2025
Operating income-$42.4M-$42.4M2025
Total assets$150.9M$150.9M2025
Liabilities$20.3M$20.3M2025
Equity$130.7M$130.7M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY22
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Reportable100%
By geography
Not disclosed.
The read
What is Ovid Therapeutics Inc.’s revenue?
Ovid Therapeutics Inc. booked $7.3M in FY2025 revenue, growing 1181% year over year — faster than 97% of Healthcare companies we track, at a -240.1% net margin.
Peers · Healthcare
COSCIENS Biopharma Inc.43DCompuMed, Inc.69BXenon Pharmaceuticals Inc.56CNewtopia Inc.——Syra Health Corp. Class A Common Stock51DMedical Imaging Corp.——Neighbors
New York →Key facts
CEOMargaret Alexander
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeNASDAQ: OVID
Employees23
IPO date2017-05-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.